SynthesisBrain pathology (Zurich, Switzerland)2010
Glioma pathophysiology: insights emerging from proteomics.
Synthesis in Brain pathology (Zurich, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas.Neurosurgical review · 2014Pooled it
- Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways.Journal of neuro-oncology · 2011Pooled it
- Identification of Prognostic Genes Related to Cell Senescence and Lipid Metabolism in Glioblastoma Based on Transcriptome and Single-Cell RNA-Seq Data.International journal of molecular sciences · 2025Article
- Targeted Glioma Therapy via TMVP1 Peptide-Modified FLT4 Liposomes: A Novel Molecular Probe Strategy.International journal of nanomedicine · 2025Article
- Case report: A unique presentation of a high-grade neuroepithelial tumor with EWSR1::PATZ1 fusion with diagnostic, molecular, and therapeutic insights.Frontiers in oncology · 2023Article
- Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival.Nature communications · 2022Article
- The Big Picture of Glioblastoma Malignancy: A Meta-Analysis of Glioblastoma Proteomics to Identify Altered Biological Pathways.ACS omega · 2021Article
- (TS)NeuroImage · 2020Article
- Principal component analysis on LC‑MS/MS and 2DE‑MALDI‑TOF in glioblastoma cell lines reveals that mitochondria act as organelle sensors of the metabolic state in glioblastoma.Oncology reports · 2020Article
- Article
- Molecular chaperones in the brain endothelial barrier: neurotoxicity or neuroprotection?FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Review
- Novel management of glioma by molecular therapies, a review article.European journal of translational myology · 2019Article
- Quantitative proteomics reveals reduction of endocytic machinery components in gliomas.EBioMedicine · 2019Article
- Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.Medicina (Kaunas, Lithuania) · 2019Review
- Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine.Frontiers in oncology · 2018Article
- Global and Targeted Pathway Impact of Gliomas on White Matter Integrity Based on Lobar Localization.Cureus · 2017Article
- Insights into molecular therapy of glioma: current challenges and next generation blueprint.Acta pharmacologica Sinica · 2017Review
- Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy.International immunopharmacology · 2014Review
- The proteomic response in glioblastoma in young patients.Journal of neuro-oncology · 2014Article
- Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics.Physiological genomics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Proteomics is increasingly employed in both neurological and oncological research to provide insight into the molecular basis of disease but rarely has a coherent, novel pathophysiological insight emerged. Gliomas account for >50% of adult primary intracranial tumors, with malignant gliomas (anaplastic astrocytomas and glioblastoma multiforme) being the most common. In glioma, the application of proteomic technology has identified altered protein expression but without consistency of these alterations or their biological significance being established. A systematic review of multiple independent proteomic analyses of glioma has demonstrated alterations of 99 different proteins. Importantly 10 of the 99 proteins found differentially expressed in glioma [PHB, Hsp20, serum albumin, epidermal growth factor receptor (EGFR), EA-15, RhoGDI, APOA1, GFAP, HSP70, PDIA3] were identified in multiple publications. An assessment of protein-protein interactions between these proteins compiled using novel web-based technology, revealed a robust and cohesive network for glioblastoma. The protein network discovered (containing TP53 and RB1 at its core) compliments recent findings in genomic studies of malignant glioma. The novel perspective provided by network analysis indicates that the potential of this technology to explore crucial aspects of glioma pathophysiology can now be realized but only if the conceptual and technical limitations highlighted in this review are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.